165 related articles for article (PubMed ID: 27259534)
1. Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models.
López de Maturana E; Picornell A; Masson-Lecomte A; Kogevinas M; Márquez M; Carrato A; Tardón A; Lloreta J; García-Closas M; Silverman D; Rothman N; Chanock S; Real FX; Goddard ME; Malats N;
BMC Cancer; 2016 Jun; 16():351. PubMed ID: 27259534
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment.
Masson-Lecomte A; López de Maturana E; Goddard ME; Picornell A; Rava M; González-Neira A; Márquez M; Carrato A; Tardon A; Lloreta J; Garcia-Closas M; Silverman D; Rothman N; Kogevinas M; Allory Y; Chanock SJ; Real FX; Malats N;
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1144-50. PubMed ID: 27197286
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
4. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
5. Whole genome prediction of bladder cancer risk with the Bayesian LASSO.
de Maturana EL; Chanok SJ; Picornell AC; Rothman N; Herranz J; Calle ML; García-Closas M; Marenne G; Brand A; Tardón A; Carrato A; Silverman DT; Kogevinas M; Gianola D; Real FX; Malats N
Genet Epidemiol; 2014 Jul; 38(5):467-76. PubMed ID: 24796258
[TBL] [Abstract][Full Text] [Related]
6. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G
Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824
[TBL] [Abstract][Full Text] [Related]
7. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
8. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer.
Chen M; Hildebrandt MA; Clague J; Kamat AM; Picornell A; Chang J; Zhang X; Izzo J; Yang H; Lin J; Gu J; Chanock S; Kogevinas M; Rothman N; Silverman DT; Garcia-Closas M; Grossman HB; Dinney CP; Malats N; Wu X
Cancer Prev Res (Phila); 2010 Oct; 3(10):1235-45. PubMed ID: 20858759
[TBL] [Abstract][Full Text] [Related]
9. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
[TBL] [Abstract][Full Text] [Related]
10. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
[TBL] [Abstract][Full Text] [Related]
11. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.
Kim JH; Park J
Hum Pathol; 2014 Sep; 45(9):1830-8. PubMed ID: 24957789
[TBL] [Abstract][Full Text] [Related]
14. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
16. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study.
Shindo T; Shimizu T; Nojima M; Niinuma T; Maruyama R; Kitajima H; Kai M; Itoh N; Suzuki H; Masumori N
Urology; 2018 Mar; 113():71-78. PubMed ID: 29196070
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer.
Chen MK; Chen ZJ; Xiao KH; Qin ZK; Ye YL; Wen WJ; Bian J; Xue KY; Zhou QZ; Guo WB; Zhou JH; Xia M; Li X; Liu CD
Jpn J Clin Oncol; 2020 Apr; 50(4):456-464. PubMed ID: 31894237
[TBL] [Abstract][Full Text] [Related]
19. RSPH9 methylation pattern as a prognostic indicator in patients with non-muscle invasive bladder cancer.
Yoon HY; Kim YJ; Kim JS; Kim YW; Kang HW; Kim WT; Yun SJ; Ryu KH; Lee SC; Kim WJ
Oncol Rep; 2016 Feb; 35(2):1195-203. PubMed ID: 26575865
[TBL] [Abstract][Full Text] [Related]
20. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
